Navigation Links
Takeda's New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis
Date:9/4/2013

60;

The BLA filings were supported by the GEMINI™ Studies, a four-study clinical program investigating vedolizumab in 2,700 patients in nearly 40 countries, making it the largest Phase 3 clinical trial program conducted to date simultaneously evaluating both CD and UC. Enrolled patients had failed at least one conventional therapy, including glucocorticoids, immunomodulators and/or a tumor necrosis factor-alpha (TNF-alpha) antagonists. TNF-alpha antagonist and conventional therapy failure patients included those with inadequate response (primary non-responders), loss of response (secondary non-responders) or those who were intolerant.

Phase 3 study results for vedolizumab were published recently in the New England Journal of Medicine.

About the GEMINI™ Studies
Announced in early 2009, the GEMINI™ Studies is a Phase 3 program evaluating the effect of vedolizumab on clinical response and remission (along with effect on mucosal healing in UC), and long-term safety in moderately to severely active CD and UC patients who had failed at least one conventional therapy or a TNF-alpha antagonist. The GEMINI program consists of four separate studies – a placebo-controlled induction and maintenance study in patients with UC (GEMINI I), a placebo-controlled induction and maintenance study in patients with CD (GEMINI II), a placebo-controlled induction study in patients with CD with prior TNF-alpha antagonist failure (GEMINI III) and an open-label long-term safety study in patients with either CD or UC (GEMINI LTS).

About Crohn's disease and ulcerative colitis
Crohn's disease (CD) and ulcerative colitis (UC) are the two most common forms of inflammatory bowel disease (IBD), which is marked by inflammation in the GI tract. CD can impact any part of the digestive tract and common symptoms may include abdominal pain, diarrhea, rectal bleeding, weight loss, and fever. UC impacts the large intestine
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
2. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
3. New Data for Abbotts Investigational High Sensitive Troponin Test Shows It May Help Doctors Predict Heart Attack Risk
4. Grifols Implements Its First Automated Inventory Management Carousel System for Investigational Pharmacies at Emory University
5. Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
6. Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
7. Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function
8. Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
9. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
10. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
11. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 Across the global ... meeting challenges in clinical development, market education, and regulatory ... the Medical Affairs function is expected to increase in ... According to research by benchmarking firm, ... a group dedicated to Medical Affairs. Among companies in ...
(Date:3/27/2015)... , March 27, 2015 /PRNewswire/ - Medicure Inc. (the ... Directors has approved the grant of an aggregate of ... employees and consultants of the Company pursuant to the ... set to expire on the tenth anniversary of the ... the third anniversary of the date of grant and ...
(Date:3/27/2015)... VICTORIA, Texas , March 27, 2015  Victoria Vein ... removal services with the Astanza Duality laser in ... of vein disease as well as advanced laser treatments for ... are entering the tattoo industry to provide more services for ... Surgery has helped many Victoria residents ...
Breaking Medicine Technology:Medical Affairs Capabilities Expanding in Emerging Marketplaces 2Victoria Vein And Surgery Clinic Uses Advanced Astanza Duality Tattoo Removal Technology 2
... Sept. 27, 2011 Masimo ... that findings from a new study published in the ... noninvasive and continuous hemoglobin (SpHb®) monitoring has absolute and ... hemoglobin measurement with additional advantages.  Study highlights that "the ...
... the United States Food and Drug Administration ("FDA") said its ... fold increase risk of blood clots for women who use ... The safety of Yaz and Yasmin is the subject ... of Common Pleas Judge Sandra Mazer Moss, Coordinating Judge of ...
Cached Medicine Technology:Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients 2Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients 3Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients 4Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients 5Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients 6FDA Issues Safety Communication Regarding Increased Risk of Blood Clots with Certain Birth Control Pills 2
(Date:3/28/2015)... March 28, 2015 Early surgery may ... Type V AC joint injuries, according to new research ... at the American Orthopaedic Society for Sports Medicine’s ( ... duty faster when surgery was not performed. , The ... receiving surgical treatment and 17 receiving non-surgical therapy. Of ...
(Date:3/28/2015)... San Francisco, California (PRWEB) March 28, 2015 ... search for original 1960's Who psychedelic concert posters. The Who ... Flushing, New York on August 2, 1968. According to Hawley, ... 1969 playing many concert halls and college campuses. Perhaps the ... their performance with Jim Morrison and the Doors on August ...
(Date:3/28/2015)... 28, 2015 Aureus Medical Group ... including physical therapy jobs, has announced that it ... Physical Therapy Association Annual Conference to be held ... Hotel in Columbus, OH. , The OPTA ... exhibits with products and services. , Representatives ...
(Date:3/28/2015)... The "Petrick Sustainable Health System" ... After 18 years of research and experience with patients ... Dr. Jon Petrick is excited to be launching his ... the immediate benefits of this radical new system are ... strength of the immune system, faster healing of injuries, ...
(Date:3/28/2015)... March 28, 2015 ARDX will sponsor the ... 12pm -3pm at the Chesapeake Conference Center in Chesapeake, Virginia. ... an empowering event for women in the Hampton Roads region. ... Stories of Women’s Lives. Women grow stronger through sharing ... other. This year the WWC™ theme is T-talk where ...
Breaking Medicine News(10 mins):Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2
... Consensus Guideline Reached For Quantitative Polymerase Chain ReactionSALT LAKE ... and the American Association for Clinical ... guideline for a key laboratory method called qPCR (or ... of international scientists representing the medical and research fields. ...
... AdCare Health Systems, Inc. (NYSE AMEX: ADK ... and management company today reported financial results for its ... December 31, 2008 were $24,793,294 as compared to $23,667,756 ... The improvement was primarily due to increased rental charges ...
... alerting capabilities, delivering meaningful performance measurements and relevant operational data ... ... Plano, TX (PRWEB) March 31, 2009 -- ... - Corepoint Decisions . Corepoint Health,s latest product ...
... 31 Hanger Orthopedic Group, Inc. (NYSE: HGR ) ... operations for the first quarter ended March 31, 2009, on ... release announcing the results for the first quarter ended March ... of the market. The conference call is scheduled to begin ...
... provider of advanced, high-volume, document and payment processing ... signed an exclusive service provider agreement with iVu ... early detection of cancer and other disease states. ... BancTec,s growing Multi-Vendor Services Group."BancTec,s Multi-Vendor Services Group ...
... League biologist who researches viruses to determine how and why ... of Houston April 2. The lecture is free and ... University associate professor of ecology and evolutionary biology, will speak ... the Science and Engineering Classroom Building Auditorium. His talk ...
Cached Medicine News:Health News:International Scientists Secure Quality in Molecular Diagnostics 2Health News:International Scientists Secure Quality in Molecular Diagnostics 3Health News:AdCare Health Systems, Inc. Reports Financial Results for 2008 2Health News:AdCare Health Systems, Inc. Reports Financial Results for 2008 3Health News:AdCare Health Systems, Inc. Reports Financial Results for 2008 4Health News:AdCare Health Systems, Inc. Reports Financial Results for 2008 5Health News:AdCare Health Systems, Inc. Reports Financial Results for 2008 6Health News:AdCare Health Systems, Inc. Reports Financial Results for 2008 7Health News:AdCare Health Systems, Inc. Reports Financial Results for 2008 8Health News:AdCare Health Systems, Inc. Reports Financial Results for 2008 9Health News:Corepoint Health Launches New Product Suite Focused on Enhancing Healthcare Operations & Metrics 2Health News:Corepoint Health Launches New Product Suite Focused on Enhancing Healthcare Operations & Metrics 3Health News:Corepoint Health Launches New Product Suite Focused on Enhancing Healthcare Operations & Metrics 4Health News:Hanger Orthopedic Group, Inc. Announces First Quarter 2009 Earnings Release Conference Call 2Health News:iVu Imaging Selects BancTec's Multi-Vendor Services Group as Exclusive Service Provider for Intelligent Volumetric Ultrasound Equipment 2Health News:iVu Imaging Selects BancTec's Multi-Vendor Services Group as Exclusive Service Provider for Intelligent Volumetric Ultrasound Equipment 3Health News:Virus evolution topic of Darwin talk at UH April 2 2
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: